{"ticker": {"uuid": "a3de1341-9ac3-48e9-b8c9-18c93f3d6516", "symbol": "LLY", "name": "Eli Lilly and Company", "exchange": "NYSE", "country": "US", "sector": "Healthcare", "industry": "Drug Manufacturers - General"}, "articles": [{"title": "Should Invesco Dividend Achievers ETF (PFM) Be on Your Investing Radar?", "summary": "Designed to provide broad exposure to the Large Cap Value segment of the US equity market, the Invesco Dividend Achievers ETF (PFM) is a passively managed exchange traded fund launched on September 15, 2005. The fund is sponsored by Invesco. It has amassed assets over $812.25 million, making it one of the average sized ETFs attempting to match the Large Cap Value segment of the US equity market. Why Large Cap Value Large cap companies usually have a market capitalization above $10 billion. Considered a more stable option, large cap companies boast more predictable cash flows and are less volat", "url": "https://finance.yahoo.com/markets/stocks/articles/invesco-dividend-achievers-etf-pfm-102001482.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-13T10:20:01+00:00", "published_display": "13 Aug 2026 10:20", "sentiment": "positive", "sentiment_pct": 58, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.531, "duplicate_count": 1, "topics": ["Dividends", "Earnings Growth", "ETF", "Financials", "Healthcare", "Institutional Investors"]}, {"title": "Berenberg Cuts Novo Nordisk as Lilly Takes the Oral Market", "summary": "This article first appeared on GuruFocus. Novo Nordisk (NYSE:NVO), the Danish drugmaker behind Wegovy and Ozempic, fell 2.23% intraday after Berenberg downgraded the stock to Hold from Buy, cutting its Copenhagen target to DKK 305 from DKK 325 and its ADR target to $47 from $50. Analyst Kerry Holford argues that the Wegovy pill upside her Buy rating was built on has already played out. Warning! GuruFocus has detected 3 Warning Sign with NVO. Is NVO fairly valued? Test your thesis with our free DCF calculator. Berenberg and broader consensus now model around DKK 15 billion of Wegovy pill sales ", "url": "https://finance.yahoo.com/healthcare/articles/berenberg-cuts-novo-nordisk-lilly-172911933.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-12T17:29:11+00:00", "published_display": "12 Aug 2026 17:29", "sentiment": "negative", "sentiment_pct": 42, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.376, "duplicate_count": 1, "topics": ["Downgrade", "Earnings", "Pharma"]}, {"title": "Eli Lilly Stock Falls While Retatrutide Lawsuits Expand", "summary": "This article first appeared on GuruFocus. Eli Lilly (NYSE:LLY), the drug giant sitting at the center of the obesity boom, filed six lawsuits against businesses it says are illegally selling retatrutide. The timing is striking. Retatrutide is not approved. It is still in Phase 3 trials. Yet Lilly says compounding pharmacies, medical spas and online vendors are already pushing unauthorized versions for human use, sometimes hiding behind research use only labels. Lilly shares slipped roughly 0.8% Wednesday morning, but this fight is much bigger than one day's stock move. Lilly is defending a drug", "url": "https://finance.yahoo.com/healthcare/articles/eli-lilly-stock-falls-while-172418737.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-12T17:24:18+00:00", "published_display": "12 Aug 2026 17:24", "sentiment": "negative", "sentiment_pct": 30, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.54, "duplicate_count": 1, "topics": ["Clinical Trials", "Lawsuits", "Obesity", "Pharma", "Quarterly Earnings"]}, {"title": "Absci (ABSI) On Early ABS 201 Data And Lilly Deal That Could Support Its Valuation", "summary": "Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Absci (ABSI) is back in focus after releasing early Phase 1 data for its lead antibody ABS-201 and securing a US$40 million investment and development support from Eli Lilly tied to the program. See our latest analysis for Absci. Absci's recent early Phase 1 ABS-201 update and Eli Lilly's US$40 million commitment arrive after a sharp run, with the share price delivering a 77.55% 90 day return and a 160.66% year to date share price return, alongside a very large 3 year total shareh", "url": "https://finance.yahoo.com/healthcare/articles/absci-absi-early-abs-201-171116760.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-12T17:11:16+00:00", "published_display": "12 Aug 2026 17:11", "sentiment": "positive", "sentiment_pct": 83, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.422, "duplicate_count": 1, "topics": ["Balance Sheet", "Biotech", "Clinical Trials", "Share Price", "Shareholder"]}, {"title": "Lilly Targets Black-Market Retatrutide Sellers", "summary": "This article first appeared on GuruFocus. Eli Lilly and Co. (LLY, Financials), the pharmaceutical company behind Zepbound and Foundayo, is stepping up its fight against unauthorized sellers of its experimental obesity drug retatrutide. Warning! GuruFocus has detected 8 Warning Sign with JPM. Is LLY fairly valued? Test your thesis with our free DCF calculator. The company filed six lawsuits against U.S. businesses it accuses of selling unapproved versions of the drug while it remains in clinical development. Retatrutide is still in Phase 3 trials for obesity, type 2 diabetes and related conditi", "url": "https://finance.yahoo.com/healthcare/articles/lilly-targets-black-market-retatrutide-165417136.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-12T16:54:17+00:00", "published_display": "12 Aug 2026 16:54", "sentiment": "negative", "sentiment_pct": 35, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.538, "duplicate_count": 1, "topics": ["Clinical Trials", "Lawsuits", "Pharma", "Regulation"]}, {"title": "Novo Nordisk Dips 4% in a Month: How Should Investors Play the Stock?", "summary": "Novo Nordisk NVO stock has declined 4% over the past month, with the company's second-quarter 2026 results emerging as the primary factor behind the recent weakness. Although NVO beat earnings and revenue estimates, investors remained concerned about underlying growth trends in its core obesity franchise. Notably, sales of injectable Wegovy for obesity were flat year over year in the second quarter, reflecting intensifying competition from rival Eli Lilly's LLY Zepbound injection and raising concerns about Novo Nordisk's ability to sustain momentum in the highly competitive GLP-1 market. Novo ", "url": "https://finance.yahoo.com/healthcare/articles/novo-nordisk-dips-4-month-151000827.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-12T15:10:00+00:00", "published_display": "12 Aug 2026 15:10", "sentiment": "positive", "sentiment_pct": 73, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.462, "duplicate_count": 1, "topics": ["Diabetes", "Earnings", "Fourth Quarter", "Guidance", "Obesity", "Pharma"]}, {"title": "Will Pfizer's Non-COVID Portfolio Drive Its Next Phase of Growth?", "summary": "Pfizer's PFE business mix has changed significantly over the past few years. During the pandemic, the company became heavily dependent on COVID-19 products, Comirnaty (COVID-19 vaccine) and Paxlovid (oral antiviral). However, the company is gradually diversifying its portfolio through a combination of internal product launches, strategic acquisitions and the continued growth of several established brands. Pfizer's non-COVID portfolio is increasingly becoming the company's primary engine of growth, helping offset the sharp decline in Comirnaty and Paxlovid revenues. The latest second-quarter 20", "url": "https://finance.yahoo.com/healthcare/articles/pfizers-non-covid-portfolio-drive-150300621.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-12T15:03:00+00:00", "published_display": "12 Aug 2026 15:03", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.254, "duplicate_count": 1, "topics": ["Earnings", "Guidance", "Obesity", "Oncology", "Pharma", "Revenue Growth"]}, {"title": "1 Vanguard ETF That Outperforms the S&P 500 and Still Has Room to Run", "summary": "Key Points The \"Magnificent Seven\" stocks account for over 53% of this Vanguard ETF. This has helped the ETF outperform the S&P 500 in 13 of the past 20 years. Sluggish performance among its top 10 holdings has slowed returns this year.10 stocks we like better than Vanguard Morningstar Growth ETF \u203a The S&P 500 is the stock market's most important index, tracking the 500 largest American companies on the market. It has become the main benchmark investors use to measure their returns, with outperformance and underperformance largely dependent on how it compares. Although investing in an S&P 500 ", "url": "https://www.nasdaq.com/articles/1-vanguard-etf-outperforms-sp-500-and-still-has-room-run", "source_name": "nasdaq.com", "published_at": "2026-08-12T14:35:00+00:00", "published_display": "12 Aug 2026 14:35", "sentiment": "neutral", "sentiment_pct": 49, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.225, "duplicate_count": 1, "topics": ["Consumer Discretionary", "ETF", "Growth Stocks", "Industrials", "Markets", "Tech"]}, {"title": "IBD 50 Stocks To Watch: Obesity Drug Giant Eli Lilly Offers New Buy Point", "summary": "Obesity-drug giant Eli Lilly stock is approaching a new buy point as the ongoing stock market rally strengthens. Continue Reading", "url": "https://finance.yahoo.com/m/fccbac36-96b9-3db5-b544-3fb53ab9e0c5/ibd-50-stocks-to-watch%3A.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-12T14:29:08+00:00", "published_display": "12 Aug 2026 14:29", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.299, "duplicate_count": 1, "topics": []}, {"title": "InduPro Closes $77 Million Series B Financing and Doses First Patient in Phase 1 Study of Lead Oncology Program IDP-001", "summary": "IDP-001 is a bispecific antibody-drug conjugate targeting EGFR and a novel Tumor-Associated Proximity Antigen identified through InduPro's proximity-guided platform Phase 1 study is enrolling adults with advanced squamous non-small cell lung cancer and other solid tumors Financing led by The Column Group, with participation from Vida Ventures, MRL Ventures Fund, Emerson Collective (advised by Yosemite), Euclidean Capital, Solasta Ventures, Sanofi, and Eli Lilly and Company SEATTLE & CAMBRIDGE, Mass., August 12, 2026--(BUSINESS WIRE)--InduPro, Inc., a biotechnology company defining membrane pro", "url": "https://finance.yahoo.com/healthcare/articles/indupro-closes-77-million-series-113000456.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-12T11:30:00+00:00", "published_display": "12 Aug 2026 11:30", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.293, "duplicate_count": 1, "topics": ["Antibody Drug Conjugates", "Biotech", "Cancer", "Clinical Trials"]}, {"title": "Lilly files six lawsuits to crack down on black market retatrutide weight-loss shots", "summary": "[Lilly Biotechnology Center in San Diego, California, USA.] JHVEPhoto Lilly escalated its fight against black-market retatrutide by filing six new lawsuits against U.S. sellers, including compounding pharmacies, medical spas, and online vendors, the drugmaker said Wednesday in a statement [https://seekingalpha.com/pr/20616057-lilly-calls-on-online-platforms-payment-companies-and-regulators-to-shut-down-the-illegal]. The company said retatrutide remains an investigational Phase 3 molecule, and no retatrutide medicine has been approved for human use by any regulator worldwide. The FDA has made c", "url": "https://seekingalpha.com/news/4631300-lilly-files-six-lawsuits-to-crack-down-on-black-market-retatrutide-weight-loss-shots?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "source_name": "seekingalpha.com", "published_at": "2026-08-12T09:41:38+00:00", "published_display": "12 Aug 2026 09:41", "sentiment": "positive", "sentiment_pct": 68, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.511, "duplicate_count": 1, "topics": ["Fda", "Pharma", "Regulation"]}, {"title": "Lilly calls on online platforms, payment companies and regulators to shut down the illegal retatrutide black market", "summary": "Files six new lawsuits as company escalates fight to protect patients INDIANAPOLIS, Aug. 12, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today escalated its continued fight to protect patients from the dangerous black market for retatrutide, filing six new lawsuits against U.S. entities selling black-market products in addition to having referred hundreds of bad actors to regulators and law enforcement worldwide. Lilly is also calling on the entities that sellers use to conduct their illegal business\u2014social media and e-commerce platforms, credit card companies, payment processors an", "url": "https://finance.yahoo.com/healthcare/articles/lilly-calls-online-platforms-payment-093000432.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-12T09:30:00+00:00", "published_display": "12 Aug 2026 09:30", "sentiment": "neutral", "sentiment_pct": 48, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.312, "duplicate_count": 1, "topics": ["Clinical Trials", "Fda Approval", "Healthcare", "Pharma", "Regulation"]}, {"title": "If I Were in My 40s, I'd Buy This Vanguard ETF Warren Buffett Recommended and Hold It Forever", "summary": "Key Points Warren Buffett steered the Berkshire Hathaway holding company to market-crushing returns for 60 years. He often said everyday investors could do well by simply buying an exchange-traded fund that tracks a diversified index like the S&P 500. In February 2014, he specifically recommended the Vanguard S&P 500 ETF because of its ultra-low fees, and it could help investors achieve a secure retirement. 10 stocks we like better than Vanguard S&P 500 ETF \u203a Warren Buffett served as chief executive officer of the Berkshire Hathaway(NYSE: BRKA)(NYSE: BRKB) holding company between 1965 and 2025", "url": "https://www.nasdaq.com/articles/if-i-were-my-40s-id-buy-vanguard-etf-warren-buffett-recommended-and-hold-it-forever", "source_name": "nasdaq.com", "published_at": "2026-08-12T09:17:00+00:00", "published_display": "12 Aug 2026 09:17", "sentiment": "neutral", "sentiment_pct": 45, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.176, "duplicate_count": 1, "topics": ["Diversification", "Etfs", "Financial Planning", "Long Term Investment", "Markets", "Tech"]}, {"title": "Absci (ABSI) Is Up 11.0% After Lilly Backs ABS-201 With US$40 Million Investment \u2013 Has The Bull Case Changed?", "summary": "Absci Corporation recently reported second-quarter 2026 results showing a net loss of US$33.21 million, wider than a year ago, while basic and diluted loss per share from continuing operations narrowed to US$0.21. Alongside these figures, Absci highlighted encouraging early Phase 1 data for ABS-201, its prolactin receptor antibody, and a US$40 million investment and development support from Eli Lilly that extend its cash runway into the second half of 2028. Next, we'll examine how Eli Lilly's US$40 million investment and advisory role could reshape Absci's investment narrative around ABS-201. ", "url": "https://finance.yahoo.com/healthcare/articles/absci-absi-11-0-lilly-071042096.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-12T07:10:42+00:00", "published_display": "12 Aug 2026 07:10", "sentiment": "negative", "sentiment_pct": 37, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.436, "duplicate_count": 1, "topics": ["Biotech", "Clinical Trials", "Earnings", "Earnings Release", "Revenue Growth"]}, {"title": "Absci Reports Business Updates and Second Quarter 2026 Financial and Operating Results", "summary": "Absci Corporation Announced positive interim Phase 1 data from the HEADLINE\u2122 trial of ABS-201 Completed $100 million underwritten offering, including $40 million strategic investment from Eli Lilly & Company Cash, cash equivalents, and marketable securities now sufficient to fund operations into the second half of 2028 VANCOUVER, Wash. and NEW YORK, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today reported financial and operating results for the quarter ended Jun", "url": "https://finance.yahoo.com/healthcare/articles/absci-reports-business-updates-second-200500755.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-11T20:05:00+00:00", "published_display": "11 Aug 2026 20:05", "sentiment": "neutral", "sentiment_pct": 47, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.246, "duplicate_count": 1, "topics": ["Balance Sheet", "Biotech", "Clinical Trials", "Fda Approval", "Fourth Quarter", "Shares Outstanding"]}, {"title": "Eli Lilly Scores Major Win in Weight-Loss Drug Race", "summary": "This article first appeared on GuruFocus. Eli Lilly (NYSE:LLY) has secured U.K. approval for its once-daily weight-loss pill Foundayo, giving the drugmaker its first regulatory win for the treatment outside the U.S. and escalating its obesity battle with Novo Nordisk. The approval expands Lilly's opportunity beyond injectable drugs such as Zepbound while giving patients a potentially simpler oral option in one of the pharmaceutical industry's fastest-growing markets. Warning! GuruFocus has detected 6 Warning Signs with INTC. Is LLY fairly valued? Test your thesis with our free DCF calculator. ", "url": "https://finance.yahoo.com/healthcare/articles/eli-lilly-scores-major-win-190732274.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-11T19:07:32+00:00", "published_display": "11 Aug 2026 19:07", "sentiment": "positive", "sentiment_pct": 72, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.46, "duplicate_count": 1, "topics": ["Fda Approval", "Obesity", "Pharma", "Regulation"]}, {"title": "2 Stocks I Think Are Hands-Down Better Picks Than SpaceX Right Now", "summary": "Space Exploration Technologies (NASDAQ: SPCX) has been perhaps the most talked-about stock on Wall Street since it completed the largest IPO ever in mid-June. Opinions on the company's prospects are divided. Some see an innovative company that has already disrupted the space travel industry and will continue to do so, and perhaps deliver life-changing returns in the process. Others see an overvalued stock that could eventually succumb to an avalanche of headwinds. Still others, like myself, split the difference: SpaceX's future looks very promising, and it could post strong returns over the lo", "url": "https://finance.yahoo.com/markets/stocks/articles/2-stocks-think-hands-down-172000205.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-11T17:20:00+00:00", "published_display": "11 Aug 2026 17:20", "sentiment": "positive", "sentiment_pct": 84, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.395, "duplicate_count": 1, "topics": ["Advertising", "AI", "Clinical Trials", "Earnings Growth", "Earnings Per Share", "Financial Results"]}, {"title": "How Much Did Immunology Drugs Contribute to AbbVie's Q2 Performance?", "summary": "AbbVie ABBV announced encouraging second-quarter 2026 results last month, which beat expectations for both earnings and sales. A significant portion of this growth came from the continued strength of its two blockbuster immunology medications, Skyrizi and Rinvoq, which together accounted for more than 47% of total revenues. Skyrizi sales jumped 24% year over year on an operational basis to $5.5 billion, while Rinvoq sales rose 23.7% to more than $2.5 billion. Both drugs benefited from strong demand and market-share gains across their approved indications, especially in the popular inflammatory", "url": "https://finance.yahoo.com/healthcare/articles/much-did-immunology-drugs-contribute-165400709.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-11T16:54:00+00:00", "published_display": "11 Aug 2026 16:54", "sentiment": "positive", "sentiment_pct": 90, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.394, "duplicate_count": 1, "topics": ["Biotech", "Competition", "Earnings", "Fda Approval", "Immunology"]}, {"title": "Lilly Takes Its Weight-Loss Pill Battle Overseas", "summary": "This article first appeared on GuruFocus. Eli Lilly and Co. (LLY, Financials), the developer of Foundayo and Zepbound, has received U.K. approval for Foundayo, the first approval for the weight-loss medication outside of the U.S. The The strategy pits Lilly directly against Novo Nordisk's Wegovy tablet in one of Europe's biggest drug marketplaces.Foundayo will initially be provided by private prescription. Availability will be wider via the U.K.'s National Health Service, subject to a review of cost efficiency.Lilly is banking on convenience to help it catch up with Novo. You can take Foundayo", "url": "https://finance.yahoo.com/healthcare/articles/lilly-takes-weight-loss-pill-151241058.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-11T15:12:41+00:00", "published_display": "11 Aug 2026 15:12", "sentiment": "positive", "sentiment_pct": 57, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.447, "duplicate_count": 1, "topics": ["Fda Approval", "Healthcare", "Pharma", "UK Approval"]}, {"title": "These stocks have some of Wall Street\u2019s lowest short interest", "summary": "[short sale] abluecup Stocks including Apple, Alphabet, Exxon Mobil, and JPMorgan are among the companies with relatively low short interest, according to a screen of stocks with market capitalizations above $2B. The screen includes stocks with short interest between 1% and 2% of shares outstanding, highlighting companies with relatively limited bearish positioning. Apple (AAPL [https://seekingalpha.com/symbol/AAPL]) has the lowest short interest in the screen at 1.00%, followed by Alphabet (GOOG [https://seekingalpha.com/symbol/GOOG]) and InnIO (INIO [https://seekingalpha.com/symbol/INIO]) at", "url": "https://seekingalpha.com/news/4629729-these-stocks-have-some-of-wall-streets-lowest-short-interest?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "source_name": "seekingalpha.com", "published_at": "2026-08-11T13:40:28+00:00", "published_display": "11 Aug 2026 13:40", "sentiment": "neutral", "sentiment_pct": 46, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.153, "duplicate_count": 1, "topics": ["Consumer Goods", "Energy", "Financials", "Shares Outstanding", "Short Interest", "Technology"]}, {"title": "J&J Trading Above 200- & 50-Day SMAs: Buy, Sell or Hold the Stock?", "summary": "Johnson & Johnson JNJ stock has been trading above both its 50-day and 200-day simple moving averages (SMAs) since mid-June. Trading above the 200-day SMA indicates that the stock's longer-term trend has turned positive, while staying above the 50-day SMA suggests that shorter-term momentum remains supportive. When a stock trades above both averages, investors generally interpret it as evidence that buying interest is strong enough to keep the shares above their medium- and long-term trend levels.Zacks Investment Research Image Source: Zacks Investment Research This strong share price performa", "url": "https://finance.yahoo.com/markets/stocks/articles/j-j-trading-above-200-131200196.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-11T13:12:00+00:00", "published_display": "11 Aug 2026 13:12", "sentiment": "positive", "sentiment_pct": 86, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.383, "duplicate_count": 1, "topics": ["Earnings", "Innovative Medicine", "Litigation", "Medtech", "Patent Expiration", "Share Price"]}, {"title": "Eli Lilly and Company (LLY) vs. Novo Nordisk A/S (NVO): Is Lilly Pulling Ahead in the $100 Billion Obesity Market?", "summary": "The duopoly dominating the multi-billion-dollar GLP-1 weight-loss market has moved from pharmacy shelves to the federal courtroom. Novo Nordisk A/S (NYSE:NVO) filed a lawsuit in U.S. District Court in New Jersey against Eli Lilly and Company (NYSE:LLY) on July 21, accusing its primary rival of false advertising and unfair competition regarding television and digital campaigns for Zepbound and Mounjaro. While both pharmaceutical giants continue to deliver massive top-line growth, a look at their underlying fundamentals shows that one company is clearly pulling ahead in execution, clinical trial", "url": "https://finance.yahoo.com/healthcare/articles/eli-lilly-company-lly-vs-124416743.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-11T12:44:16+00:00", "published_display": "11 Aug 2026 12:44", "sentiment": "negative", "sentiment_pct": 33, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.439, "duplicate_count": 1, "topics": ["Clinical Trials", "Financial Results", "Lawsuit", "Net Income", "Obesity Treatment", "Pharma"]}, {"title": "Veeva Vault CRM Selected by Eli Lilly and Company", "summary": "PLEASANTON, Calif., Aug. 11, 2026 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that Eli Lilly and Company (Lilly) has committed to Veeva Vault CRM globally.Veeva Vault CRM Selected by Eli Lilly and Company Vault CRM is part of the Vault CRM Suite of applications that provides the technology foundation for agentic commercial, the new commercial model that leverages AI to get the right medicines to more patients. \"We are excited to expand our strategic work with Veeva by moving to Vault CRM,\" said Giuseppe Firenze, senior vice president, U.S. HCP and field engagement hub at Lilly. ", "url": "https://finance.yahoo.com/healthcare/articles/veeva-vault-crm-selected-eli-110300980.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-11T11:03:00+00:00", "published_display": "11 Aug 2026 11:03", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.245, "duplicate_count": 1, "topics": ["Biotech", "Crm", "Pharma"]}, {"title": "Eli Lilly's Foundayo Wins UK Approval", "summary": "(RTTNews) - Eli Lilly and Company's (LLY) oral GLP-1 pill Foundayo has secured UK regulatory approval for weight management and type 2 diabetes, making the UK the first European country to clear the once-daily tablet. The decision by the Medicines and Healthcare products Regulatory Agency (MHRA) on August 10, 2026, follows the U.S. FDA's approval in April 2026, positioning Foundayo as a key entrant in the competitive obesity and diabetes market. Foundayo (orforglipron) is a small-molecule GLP-1 receptor agonist designed for convenient daily use without food or water restrictions. Clinical data", "url": "https://www.nasdaq.com/articles/eli-lillys-foundayo-wins-uk-approval", "source_name": "nasdaq.com", "published_at": "2026-08-11T07:30:37+00:00", "published_display": "11 Aug 2026 07:30", "sentiment": "positive", "sentiment_pct": 60, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.423, "duplicate_count": 1, "topics": ["Biotech", "Diabetes", "Earnings", "Fda Approval", "Pharma", "Regulation"]}, {"title": "Eli Lilly (LLY) Stock Gets Fair Value Bump After GLP 1 Driven Analyst Revisions", "summary": "Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Eli Lilly's updated fair value price target has shifted from US$1,270.37 to US$1,297.31, giving investors a fresh reference point for how analysts are framing the stock today. Much of this reset is tied to recent Street commentary that focuses on incretin and GLP-1 therapies, Q2 results, and the potential of assets like Mounjaro, Zepbound, retatrutide and Foundayo. As you read on, you will see how to track these moving parts and keep up with the evolving Eli Lilly narrative. Stay ", "url": "https://finance.yahoo.com/markets/stocks/articles/eli-lilly-lly-stock-gets-232051909.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-10T23:20:51+00:00", "published_display": "10 Aug 2026 23:20", "sentiment": "positive", "sentiment_pct": 83, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.347, "duplicate_count": 1, "topics": ["Diabetes", "Earnings", "Obesity", "Pharma", "Price Target", "Price Target"]}, {"title": "Eli Lilly vs. Novo Nordisk: Which Company Is Better Positioned for America\u2019s New Drug Manufacturing Policies?", "summary": "For years, investors have viewed Eli Lilly (NYSE:LLY) and Novo Nordisk (NYSE:NVO) through one lens: the race to dominate the booming obesity-drug market. But Washington is beginning to shift the conversation. With the U.S. government pushing pharmaceutical companies to manufacture more medicines domestically and reduce dependence on overseas supply chains, manufacturing has become more of a competitive advantage than an operational consideration. That shift creates a new question for investors. If domestic manufacturing becomes a larger determinant of pricing, regulatory flexibility, and suppl", "url": "https://finance.yahoo.com/healthcare/articles/eli-lilly-vs-novo-nordisk-222158536.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-10T22:21:58+00:00", "published_display": "10 Aug 2026 22:21", "sentiment": "positive", "sentiment_pct": 61, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.344, "duplicate_count": 1, "topics": ["Fda", "Manufacturing", "Obesity Drugs", "Pharma", "Revenue Growth", "Shareholder"]}], "by_tier": {"direct": [{"title": "Should Invesco Dividend Achievers ETF (PFM) Be on Your Investing Radar?", "summary": "Designed to provide broad exposure to the Large Cap Value segment of the US equity market, the Invesco Dividend Achievers ETF (PFM) is a passively managed exchange traded fund launched on September 15, 2005. The fund is sponsored by Invesco. It has amassed assets over $812.25 million, making it one of the average sized ETFs attempting to match the Large Cap Value segment of the US equity market. Why Large Cap Value Large cap companies usually have a market capitalization above $10 billion. Considered a more stable option, large cap companies boast more predictable cash flows and are less volat", "url": "https://finance.yahoo.com/markets/stocks/articles/invesco-dividend-achievers-etf-pfm-102001482.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-13T10:20:01+00:00", "published_display": "13 Aug 2026 10:20", "provider": "eodhd", "sentiment": "positive", "sentiment_pct": 58, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.531, "duplicate_count": 1, "topics": ["Dividends", "Earnings Growth", "ETF", "Financials", "Healthcare", "Institutional Investors"]}, {"title": "Berenberg Cuts Novo Nordisk as Lilly Takes the Oral Market", "summary": "This article first appeared on GuruFocus. Novo Nordisk (NYSE:NVO), the Danish drugmaker behind Wegovy and Ozempic, fell 2.23% intraday after Berenberg downgraded the stock to Hold from Buy, cutting its Copenhagen target to DKK 305 from DKK 325 and its ADR target to $47 from $50. Analyst Kerry Holford argues that the Wegovy pill upside her Buy rating was built on has already played out. Warning! GuruFocus has detected 3 Warning Sign with NVO. Is NVO fairly valued? Test your thesis with our free DCF calculator. Berenberg and broader consensus now model around DKK 15 billion of Wegovy pill sales ", "url": "https://finance.yahoo.com/healthcare/articles/berenberg-cuts-novo-nordisk-lilly-172911933.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-12T17:29:11+00:00", "published_display": "12 Aug 2026 17:29", "provider": "eodhd", "sentiment": "negative", "sentiment_pct": 42, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.376, "duplicate_count": 1, "topics": ["Downgrade", "Earnings", "Pharma"]}, {"title": "Eli Lilly Stock Falls While Retatrutide Lawsuits Expand", "summary": "This article first appeared on GuruFocus. Eli Lilly (NYSE:LLY), the drug giant sitting at the center of the obesity boom, filed six lawsuits against businesses it says are illegally selling retatrutide. The timing is striking. Retatrutide is not approved. It is still in Phase 3 trials. Yet Lilly says compounding pharmacies, medical spas and online vendors are already pushing unauthorized versions for human use, sometimes hiding behind research use only labels. Lilly shares slipped roughly 0.8% Wednesday morning, but this fight is much bigger than one day's stock move. Lilly is defending a drug", "url": "https://finance.yahoo.com/healthcare/articles/eli-lilly-stock-falls-while-172418737.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-12T17:24:18+00:00", "published_display": "12 Aug 2026 17:24", "provider": "eodhd", "sentiment": "negative", "sentiment_pct": 30, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.54, "duplicate_count": 1, "topics": ["Clinical Trials", "Lawsuits", "Obesity", "Pharma", "Quarterly Earnings"]}, {"title": "Absci (ABSI) On Early ABS 201 Data And Lilly Deal That Could Support Its Valuation", "summary": "Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Absci (ABSI) is back in focus after releasing early Phase 1 data for its lead antibody ABS-201 and securing a US$40 million investment and development support from Eli Lilly tied to the program. See our latest analysis for Absci. Absci's recent early Phase 1 ABS-201 update and Eli Lilly's US$40 million commitment arrive after a sharp run, with the share price delivering a 77.55% 90 day return and a 160.66% year to date share price return, alongside a very large 3 year total shareh", "url": "https://finance.yahoo.com/healthcare/articles/absci-absi-early-abs-201-171116760.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-12T17:11:16+00:00", "published_display": "12 Aug 2026 17:11", "provider": "eodhd", "sentiment": "positive", "sentiment_pct": 83, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.422, "duplicate_count": 1, "topics": ["Balance Sheet", "Biotech", "Clinical Trials", "Share Price", "Shareholder"]}, {"title": "Lilly Targets Black-Market Retatrutide Sellers", "summary": "This article first appeared on GuruFocus. Eli Lilly and Co. (LLY, Financials), the pharmaceutical company behind Zepbound and Foundayo, is stepping up its fight against unauthorized sellers of its experimental obesity drug retatrutide. Warning! GuruFocus has detected 8 Warning Sign with JPM. Is LLY fairly valued? Test your thesis with our free DCF calculator. The company filed six lawsuits against U.S. businesses it accuses of selling unapproved versions of the drug while it remains in clinical development. Retatrutide is still in Phase 3 trials for obesity, type 2 diabetes and related conditi", "url": "https://finance.yahoo.com/healthcare/articles/lilly-targets-black-market-retatrutide-165417136.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-12T16:54:17+00:00", "published_display": "12 Aug 2026 16:54", "provider": "eodhd", "sentiment": "negative", "sentiment_pct": 35, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.538, "duplicate_count": 1, "topics": ["Clinical Trials", "Lawsuits", "Pharma", "Regulation"]}, {"title": "Novo Nordisk Dips 4% in a Month: How Should Investors Play the Stock?", "summary": "Novo Nordisk NVO stock has declined 4% over the past month, with the company's second-quarter 2026 results emerging as the primary factor behind the recent weakness. Although NVO beat earnings and revenue estimates, investors remained concerned about underlying growth trends in its core obesity franchise. Notably, sales of injectable Wegovy for obesity were flat year over year in the second quarter, reflecting intensifying competition from rival Eli Lilly's LLY Zepbound injection and raising concerns about Novo Nordisk's ability to sustain momentum in the highly competitive GLP-1 market. Novo ", "url": "https://finance.yahoo.com/healthcare/articles/novo-nordisk-dips-4-month-151000827.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-12T15:10:00+00:00", "published_display": "12 Aug 2026 15:10", "provider": "eodhd", "sentiment": "positive", "sentiment_pct": 73, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.462, "duplicate_count": 1, "topics": ["Diabetes", "Earnings", "Fourth Quarter", "Guidance", "Obesity", "Pharma"]}, {"title": "Will Pfizer's Non-COVID Portfolio Drive Its Next Phase of Growth?", "summary": "Pfizer's PFE business mix has changed significantly over the past few years. During the pandemic, the company became heavily dependent on COVID-19 products, Comirnaty (COVID-19 vaccine) and Paxlovid (oral antiviral). However, the company is gradually diversifying its portfolio through a combination of internal product launches, strategic acquisitions and the continued growth of several established brands. Pfizer's non-COVID portfolio is increasingly becoming the company's primary engine of growth, helping offset the sharp decline in Comirnaty and Paxlovid revenues. The latest second-quarter 20", "url": "https://finance.yahoo.com/healthcare/articles/pfizers-non-covid-portfolio-drive-150300621.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-12T15:03:00+00:00", "published_display": "12 Aug 2026 15:03", "provider": "eodhd", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.254, "duplicate_count": 1, "topics": ["Earnings", "Guidance", "Obesity", "Oncology", "Pharma", "Revenue Growth"]}, {"title": "1 Vanguard ETF That Outperforms the S&P 500 and Still Has Room to Run", "summary": "Key Points The \"Magnificent Seven\" stocks account for over 53% of this Vanguard ETF. This has helped the ETF outperform the S&P 500 in 13 of the past 20 years. Sluggish performance among its top 10 holdings has slowed returns this year.10 stocks we like better than Vanguard Morningstar Growth ETF \u203a The S&P 500 is the stock market's most important index, tracking the 500 largest American companies on the market. It has become the main benchmark investors use to measure their returns, with outperformance and underperformance largely dependent on how it compares. Although investing in an S&P 500 ", "url": "https://www.nasdaq.com/articles/1-vanguard-etf-outperforms-sp-500-and-still-has-room-run", "source_name": "nasdaq.com", "published_at": "2026-08-12T14:35:00+00:00", "published_display": "12 Aug 2026 14:35", "provider": "eodhd", "sentiment": "neutral", "sentiment_pct": 49, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.225, "duplicate_count": 1, "topics": ["Consumer Discretionary", "ETF", "Growth Stocks", "Industrials", "Markets", "Tech"]}, {"title": "IBD 50 Stocks To Watch: Obesity Drug Giant Eli Lilly Offers New Buy Point", "summary": "Obesity-drug giant Eli Lilly stock is approaching a new buy point as the ongoing stock market rally strengthens. Continue Reading", "url": "https://finance.yahoo.com/m/fccbac36-96b9-3db5-b544-3fb53ab9e0c5/ibd-50-stocks-to-watch%3A.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-12T14:29:08+00:00", "published_display": "12 Aug 2026 14:29", "provider": "eodhd", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.299, "duplicate_count": 1, "topics": []}, {"title": "InduPro Closes $77 Million Series B Financing and Doses First Patient in Phase 1 Study of Lead Oncology Program IDP-001", "summary": "IDP-001 is a bispecific antibody-drug conjugate targeting EGFR and a novel Tumor-Associated Proximity Antigen identified through InduPro's proximity-guided platform Phase 1 study is enrolling adults with advanced squamous non-small cell lung cancer and other solid tumors Financing led by The Column Group, with participation from Vida Ventures, MRL Ventures Fund, Emerson Collective (advised by Yosemite), Euclidean Capital, Solasta Ventures, Sanofi, and Eli Lilly and Company SEATTLE & CAMBRIDGE, Mass., August 12, 2026--(BUSINESS WIRE)--InduPro, Inc., a biotechnology company defining membrane pro", "url": "https://finance.yahoo.com/healthcare/articles/indupro-closes-77-million-series-113000456.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-12T11:30:00+00:00", "published_display": "12 Aug 2026 11:30", "provider": "eodhd", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.293, "duplicate_count": 1, "topics": ["Antibody Drug Conjugates", "Biotech", "Cancer", "Clinical Trials"]}, {"title": "Lilly files six lawsuits to crack down on black market retatrutide weight-loss shots", "summary": "[Lilly Biotechnology Center in San Diego, California, USA.] JHVEPhoto Lilly escalated its fight against black-market retatrutide by filing six new lawsuits against U.S. sellers, including compounding pharmacies, medical spas, and online vendors, the drugmaker said Wednesday in a statement [https://seekingalpha.com/pr/20616057-lilly-calls-on-online-platforms-payment-companies-and-regulators-to-shut-down-the-illegal]. The company said retatrutide remains an investigational Phase 3 molecule, and no retatrutide medicine has been approved for human use by any regulator worldwide. The FDA has made c", "url": "https://seekingalpha.com/news/4631300-lilly-files-six-lawsuits-to-crack-down-on-black-market-retatrutide-weight-loss-shots?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "source_name": "seekingalpha.com", "published_at": "2026-08-12T09:41:38+00:00", "published_display": "12 Aug 2026 09:41", "provider": "eodhd", "sentiment": "positive", "sentiment_pct": 68, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.511, "duplicate_count": 1, "topics": ["Fda", "Pharma", "Regulation"]}, {"title": "Lilly calls on online platforms, payment companies and regulators to shut down the illegal retatrutide black market", "summary": "Files six new lawsuits as company escalates fight to protect patients INDIANAPOLIS, Aug. 12, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today escalated its continued fight to protect patients from the dangerous black market for retatrutide, filing six new lawsuits against U.S. entities selling black-market products in addition to having referred hundreds of bad actors to regulators and law enforcement worldwide. Lilly is also calling on the entities that sellers use to conduct their illegal business\u2014social media and e-commerce platforms, credit card companies, payment processors an", "url": "https://finance.yahoo.com/healthcare/articles/lilly-calls-online-platforms-payment-093000432.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-12T09:30:00+00:00", "published_display": "12 Aug 2026 09:30", "provider": "eodhd", "sentiment": "neutral", "sentiment_pct": 48, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.312, "duplicate_count": 1, "topics": ["Clinical Trials", "Fda Approval", "Healthcare", "Pharma", "Regulation"]}, {"title": "If I Were in My 40s, I'd Buy This Vanguard ETF Warren Buffett Recommended and Hold It Forever", "summary": "Key Points Warren Buffett steered the Berkshire Hathaway holding company to market-crushing returns for 60 years. He often said everyday investors could do well by simply buying an exchange-traded fund that tracks a diversified index like the S&P 500. In February 2014, he specifically recommended the Vanguard S&P 500 ETF because of its ultra-low fees, and it could help investors achieve a secure retirement. 10 stocks we like better than Vanguard S&P 500 ETF \u203a Warren Buffett served as chief executive officer of the Berkshire Hathaway(NYSE: BRKA)(NYSE: BRKB) holding company between 1965 and 2025", "url": "https://www.nasdaq.com/articles/if-i-were-my-40s-id-buy-vanguard-etf-warren-buffett-recommended-and-hold-it-forever", "source_name": "nasdaq.com", "published_at": "2026-08-12T09:17:00+00:00", "published_display": "12 Aug 2026 09:17", "provider": "eodhd", "sentiment": "neutral", "sentiment_pct": 45, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.176, "duplicate_count": 1, "topics": ["Diversification", "Etfs", "Financial Planning", "Long Term Investment", "Markets", "Tech"]}, {"title": "Absci (ABSI) Is Up 11.0% After Lilly Backs ABS-201 With US$40 Million Investment \u2013 Has The Bull Case Changed?", "summary": "Absci Corporation recently reported second-quarter 2026 results showing a net loss of US$33.21 million, wider than a year ago, while basic and diluted loss per share from continuing operations narrowed to US$0.21. Alongside these figures, Absci highlighted encouraging early Phase 1 data for ABS-201, its prolactin receptor antibody, and a US$40 million investment and development support from Eli Lilly that extend its cash runway into the second half of 2028. Next, we'll examine how Eli Lilly's US$40 million investment and advisory role could reshape Absci's investment narrative around ABS-201. ", "url": "https://finance.yahoo.com/healthcare/articles/absci-absi-11-0-lilly-071042096.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-12T07:10:42+00:00", "published_display": "12 Aug 2026 07:10", "provider": "eodhd", "sentiment": "negative", "sentiment_pct": 37, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.436, "duplicate_count": 1, "topics": ["Biotech", "Clinical Trials", "Earnings", "Earnings Release", "Revenue Growth"]}, {"title": "Absci Reports Business Updates and Second Quarter 2026 Financial and Operating Results", "summary": "Absci Corporation Announced positive interim Phase 1 data from the HEADLINE\u2122 trial of ABS-201 Completed $100 million underwritten offering, including $40 million strategic investment from Eli Lilly & Company Cash, cash equivalents, and marketable securities now sufficient to fund operations into the second half of 2028 VANCOUVER, Wash. and NEW YORK, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today reported financial and operating results for the quarter ended Jun", "url": "https://finance.yahoo.com/healthcare/articles/absci-reports-business-updates-second-200500755.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-11T20:05:00+00:00", "published_display": "11 Aug 2026 20:05", "provider": "eodhd", "sentiment": "neutral", "sentiment_pct": 47, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.246, "duplicate_count": 1, "topics": ["Balance Sheet", "Biotech", "Clinical Trials", "Fda Approval", "Fourth Quarter", "Shares Outstanding"]}, {"title": "Eli Lilly Scores Major Win in Weight-Loss Drug Race", "summary": "This article first appeared on GuruFocus. Eli Lilly (NYSE:LLY) has secured U.K. approval for its once-daily weight-loss pill Foundayo, giving the drugmaker its first regulatory win for the treatment outside the U.S. and escalating its obesity battle with Novo Nordisk. The approval expands Lilly's opportunity beyond injectable drugs such as Zepbound while giving patients a potentially simpler oral option in one of the pharmaceutical industry's fastest-growing markets. Warning! GuruFocus has detected 6 Warning Signs with INTC. Is LLY fairly valued? Test your thesis with our free DCF calculator. ", "url": "https://finance.yahoo.com/healthcare/articles/eli-lilly-scores-major-win-190732274.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-11T19:07:32+00:00", "published_display": "11 Aug 2026 19:07", "provider": "eodhd", "sentiment": "positive", "sentiment_pct": 72, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.46, "duplicate_count": 1, "topics": ["Fda Approval", "Obesity", "Pharma", "Regulation"]}, {"title": "2 Stocks I Think Are Hands-Down Better Picks Than SpaceX Right Now", "summary": "Space Exploration Technologies (NASDAQ: SPCX) has been perhaps the most talked-about stock on Wall Street since it completed the largest IPO ever in mid-June. Opinions on the company's prospects are divided. Some see an innovative company that has already disrupted the space travel industry and will continue to do so, and perhaps deliver life-changing returns in the process. Others see an overvalued stock that could eventually succumb to an avalanche of headwinds. Still others, like myself, split the difference: SpaceX's future looks very promising, and it could post strong returns over the lo", "url": "https://finance.yahoo.com/markets/stocks/articles/2-stocks-think-hands-down-172000205.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-11T17:20:00+00:00", "published_display": "11 Aug 2026 17:20", "provider": "eodhd", "sentiment": "positive", "sentiment_pct": 84, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.395, "duplicate_count": 1, "topics": ["Advertising", "AI", "Clinical Trials", "Earnings Growth", "Earnings Per Share", "Financial Results"]}, {"title": "How Much Did Immunology Drugs Contribute to AbbVie's Q2 Performance?", "summary": "AbbVie ABBV announced encouraging second-quarter 2026 results last month, which beat expectations for both earnings and sales. A significant portion of this growth came from the continued strength of its two blockbuster immunology medications, Skyrizi and Rinvoq, which together accounted for more than 47% of total revenues. Skyrizi sales jumped 24% year over year on an operational basis to $5.5 billion, while Rinvoq sales rose 23.7% to more than $2.5 billion. Both drugs benefited from strong demand and market-share gains across their approved indications, especially in the popular inflammatory", "url": "https://finance.yahoo.com/healthcare/articles/much-did-immunology-drugs-contribute-165400709.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-11T16:54:00+00:00", "published_display": "11 Aug 2026 16:54", "provider": "eodhd", "sentiment": "positive", "sentiment_pct": 90, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.394, "duplicate_count": 1, "topics": ["Biotech", "Competition", "Earnings", "Fda Approval", "Immunology"]}, {"title": "Lilly Takes Its Weight-Loss Pill Battle Overseas", "summary": "This article first appeared on GuruFocus. Eli Lilly and Co. (LLY, Financials), the developer of Foundayo and Zepbound, has received U.K. approval for Foundayo, the first approval for the weight-loss medication outside of the U.S. The The strategy pits Lilly directly against Novo Nordisk's Wegovy tablet in one of Europe's biggest drug marketplaces.Foundayo will initially be provided by private prescription. Availability will be wider via the U.K.'s National Health Service, subject to a review of cost efficiency.Lilly is banking on convenience to help it catch up with Novo. You can take Foundayo", "url": "https://finance.yahoo.com/healthcare/articles/lilly-takes-weight-loss-pill-151241058.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-11T15:12:41+00:00", "published_display": "11 Aug 2026 15:12", "provider": "eodhd", "sentiment": "positive", "sentiment_pct": 57, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.447, "duplicate_count": 1, "topics": ["Fda Approval", "Healthcare", "Pharma", "UK Approval"]}, {"title": "These stocks have some of Wall Street\u2019s lowest short interest", "summary": "[short sale] abluecup Stocks including Apple, Alphabet, Exxon Mobil, and JPMorgan are among the companies with relatively low short interest, according to a screen of stocks with market capitalizations above $2B. The screen includes stocks with short interest between 1% and 2% of shares outstanding, highlighting companies with relatively limited bearish positioning. Apple (AAPL [https://seekingalpha.com/symbol/AAPL]) has the lowest short interest in the screen at 1.00%, followed by Alphabet (GOOG [https://seekingalpha.com/symbol/GOOG]) and InnIO (INIO [https://seekingalpha.com/symbol/INIO]) at", "url": "https://seekingalpha.com/news/4629729-these-stocks-have-some-of-wall-streets-lowest-short-interest?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "source_name": "seekingalpha.com", "published_at": "2026-08-11T13:40:28+00:00", "published_display": "11 Aug 2026 13:40", "provider": "eodhd", "sentiment": "neutral", "sentiment_pct": 46, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.153, "duplicate_count": 1, "topics": ["Consumer Goods", "Energy", "Financials", "Shares Outstanding", "Short Interest", "Technology"]}, {"title": "J&J Trading Above 200- & 50-Day SMAs: Buy, Sell or Hold the Stock?", "summary": "Johnson & Johnson JNJ stock has been trading above both its 50-day and 200-day simple moving averages (SMAs) since mid-June. Trading above the 200-day SMA indicates that the stock's longer-term trend has turned positive, while staying above the 50-day SMA suggests that shorter-term momentum remains supportive. When a stock trades above both averages, investors generally interpret it as evidence that buying interest is strong enough to keep the shares above their medium- and long-term trend levels.Zacks Investment Research Image Source: Zacks Investment Research This strong share price performa", "url": "https://finance.yahoo.com/markets/stocks/articles/j-j-trading-above-200-131200196.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-11T13:12:00+00:00", "published_display": "11 Aug 2026 13:12", "provider": "eodhd", "sentiment": "positive", "sentiment_pct": 86, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.383, "duplicate_count": 1, "topics": ["Earnings", "Innovative Medicine", "Litigation", "Medtech", "Patent Expiration", "Share Price"]}, {"title": "Eli Lilly and Company (LLY) vs. Novo Nordisk A/S (NVO): Is Lilly Pulling Ahead in the $100 Billion Obesity Market?", "summary": "The duopoly dominating the multi-billion-dollar GLP-1 weight-loss market has moved from pharmacy shelves to the federal courtroom. Novo Nordisk A/S (NYSE:NVO) filed a lawsuit in U.S. District Court in New Jersey against Eli Lilly and Company (NYSE:LLY) on July 21, accusing its primary rival of false advertising and unfair competition regarding television and digital campaigns for Zepbound and Mounjaro. While both pharmaceutical giants continue to deliver massive top-line growth, a look at their underlying fundamentals shows that one company is clearly pulling ahead in execution, clinical trial", "url": "https://finance.yahoo.com/healthcare/articles/eli-lilly-company-lly-vs-124416743.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-11T12:44:16+00:00", "published_display": "11 Aug 2026 12:44", "provider": "eodhd", "sentiment": "negative", "sentiment_pct": 33, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.439, "duplicate_count": 1, "topics": ["Clinical Trials", "Financial Results", "Lawsuit", "Net Income", "Obesity Treatment", "Pharma"]}, {"title": "Veeva Vault CRM Selected by Eli Lilly and Company", "summary": "PLEASANTON, Calif., Aug. 11, 2026 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that Eli Lilly and Company (Lilly) has committed to Veeva Vault CRM globally.Veeva Vault CRM Selected by Eli Lilly and Company Vault CRM is part of the Vault CRM Suite of applications that provides the technology foundation for agentic commercial, the new commercial model that leverages AI to get the right medicines to more patients. \"We are excited to expand our strategic work with Veeva by moving to Vault CRM,\" said Giuseppe Firenze, senior vice president, U.S. HCP and field engagement hub at Lilly. ", "url": "https://finance.yahoo.com/healthcare/articles/veeva-vault-crm-selected-eli-110300980.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-11T11:03:00+00:00", "published_display": "11 Aug 2026 11:03", "provider": "eodhd", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.245, "duplicate_count": 1, "topics": ["Biotech", "Crm", "Pharma"]}, {"title": "Eli Lilly's Foundayo Wins UK Approval", "summary": "(RTTNews) - Eli Lilly and Company's (LLY) oral GLP-1 pill Foundayo has secured UK regulatory approval for weight management and type 2 diabetes, making the UK the first European country to clear the once-daily tablet. The decision by the Medicines and Healthcare products Regulatory Agency (MHRA) on August 10, 2026, follows the U.S. FDA's approval in April 2026, positioning Foundayo as a key entrant in the competitive obesity and diabetes market. Foundayo (orforglipron) is a small-molecule GLP-1 receptor agonist designed for convenient daily use without food or water restrictions. Clinical data", "url": "https://www.nasdaq.com/articles/eli-lillys-foundayo-wins-uk-approval", "source_name": "nasdaq.com", "published_at": "2026-08-11T07:30:37+00:00", "published_display": "11 Aug 2026 07:30", "provider": "eodhd", "sentiment": "positive", "sentiment_pct": 60, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.423, "duplicate_count": 1, "topics": ["Biotech", "Diabetes", "Earnings", "Fda Approval", "Pharma", "Regulation"]}, {"title": "Eli Lilly (LLY) Stock Gets Fair Value Bump After GLP 1 Driven Analyst Revisions", "summary": "Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Eli Lilly's updated fair value price target has shifted from US$1,270.37 to US$1,297.31, giving investors a fresh reference point for how analysts are framing the stock today. Much of this reset is tied to recent Street commentary that focuses on incretin and GLP-1 therapies, Q2 results, and the potential of assets like Mounjaro, Zepbound, retatrutide and Foundayo. As you read on, you will see how to track these moving parts and keep up with the evolving Eli Lilly narrative. Stay ", "url": "https://finance.yahoo.com/markets/stocks/articles/eli-lilly-lly-stock-gets-232051909.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-10T23:20:51+00:00", "published_display": "10 Aug 2026 23:20", "provider": "eodhd", "sentiment": "positive", "sentiment_pct": 83, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.347, "duplicate_count": 1, "topics": ["Diabetes", "Earnings", "Obesity", "Pharma", "Price Target", "Price Target"]}, {"title": "Eli Lilly vs. Novo Nordisk: Which Company Is Better Positioned for America\u2019s New Drug Manufacturing Policies?", "summary": "For years, investors have viewed Eli Lilly (NYSE:LLY) and Novo Nordisk (NYSE:NVO) through one lens: the race to dominate the booming obesity-drug market. But Washington is beginning to shift the conversation. With the U.S. government pushing pharmaceutical companies to manufacture more medicines domestically and reduce dependence on overseas supply chains, manufacturing has become more of a competitive advantage than an operational consideration. That shift creates a new question for investors. If domestic manufacturing becomes a larger determinant of pricing, regulatory flexibility, and suppl", "url": "https://finance.yahoo.com/healthcare/articles/eli-lilly-vs-novo-nordisk-222158536.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-10T22:21:58+00:00", "published_display": "10 Aug 2026 22:21", "provider": "eodhd", "sentiment": "positive", "sentiment_pct": 61, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.344, "duplicate_count": 1, "topics": ["Fda", "Manufacturing", "Obesity Drugs", "Pharma", "Revenue Growth", "Shareholder"]}], "industry": [], "sector": []}, "total_fetched": 26, "total_unique": 26, "total_relevant": 26, "pipeline_health": {"providers_attempted": 1, "providers_with_results": 1, "provider_counts": {"eodhd": 27}, "raw_articles": 27, "unique_stories": 26, "duplicates_removed": 1, "relevant_stories": 26, "current_evidence": 26, "direct_evidence": 26, "eodhd_articles": 26, "eodhd": {"configured": true, "status": "healthy", "calls_used": 335, "call_budget": 500, "budget_used_pct": 67.0, "requests_made": 67, "last_success_at": "2026-08-13T12:30:18.563687+00:00", "newest_seen_at": "2026-08-13T12:13:24+00:00", "rate_limit": 1200, "rate_remaining": 1199, "last_error": "", "mapped_mentions": 2955, "unmapped_mentions": 2031}, "status": "healthy", "durable_evidence_used": true, "durable_collected_at": "2026-08-13T05:47:45.110020+00:00", "durable_newest_article_at": "2026-08-12T17:29:11+00:00", "durable_story_count": 1}, "sentiment_summary": {"positive": 15, "negative": 5, "neutral": 6, "score": 58, "raw_score": 59, "total": 26, "evidence_count": 26, "effective_articles": 23.94, "direct_story_count": 26, "industry_story_count": 0, "sector_story_count": 0, "story_count": 26, "source_count": 3, "source_concentration": 0.7275, "direct_share": 100, "dispersion": 18, "confidence": 84, "evidence_status": "measured", "score_version": "evidence-v4", "newest_article_at": "2026-08-13T10:20:01+00:00", "label": "Constructive news tone", "tone": "positive"}, "classifier": {"primary_event": "earnings", "primary_label": "Earnings", "confidence": 72, "events": [{"event": "earnings", "label": "Earnings", "weight": 5.4, "count": 9}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 4.8, "count": 8}, {"event": "general", "label": "Market update", "weight": 3.0, "count": 5}, {"event": "analyst", "label": "Analyst action", "weight": 1.2, "count": 2}, {"event": "deals", "label": "Deals and strategy", "weight": 1.2, "count": 2}], "positive_events": 15, "negative_events": 5, "pipeline": {"providers_attempted": 1, "providers_with_results": 1, "provider_counts": {"eodhd": 27}, "raw_articles": 27, "unique_stories": 26, "duplicates_removed": 1, "relevant_stories": 26, "current_evidence": 26, "direct_evidence": 26, "eodhd_articles": 26, "eodhd": {"configured": true, "status": "healthy", "calls_used": 335, "call_budget": 500, "budget_used_pct": 67.0, "requests_made": 67, "last_success_at": "2026-08-13T12:30:18.563687+00:00", "newest_seen_at": "2026-08-13T12:13:24+00:00", "rate_limit": 1200, "rate_remaining": 1199, "last_error": "", "mapped_mentions": 2955, "unmapped_mentions": 2031}, "status": "healthy", "durable_evidence_used": true, "durable_collected_at": "2026-08-13T05:47:45.110020+00:00", "durable_newest_article_at": "2026-08-12T17:29:11+00:00", "durable_story_count": 1}}, "market_context": {"has_market_context": true, "latest_close": 1185.71, "latest_week": "2026-08-07", "one_week_move": 3.2, "four_week_move": -0.2, "twelve_week_move": 18.0, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 0.688583, "market_dynamics_buy_signal": false, "relative_strength": 8.06057, "fair_value_gap": 43.2, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "positive", "expectation_probability": 58.1524, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+3.2% over one week, -0.2% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "News confirmed by price", "tone": "positive", "classification": "confirmed_positive", "summary": "Constructive news tone is being confirmed by positive weekly price action.", "confidence": 69, "badges": ["Sentiment confirms active trend", "Positive but stretched"], "opportunities": ["Constructive tone aligns with the Sharemaestro trend signal."], "risks": ["Constructive tone is arriving with price materially above fair value."], "event_label": "Earnings", "sentiment_word": "constructive"}, "charts": {"sources": [{"label": "finance.yahoo.com", "count": 21}, {"label": "nasdaq.com", "count": 3}, {"label": "seekingalpha.com", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 26}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Earnings", "count": 9}, {"label": "Regulatory and legal", "count": 8}, {"label": "Market update", "count": 5}, {"label": "Analyst action", "count": 2}, {"label": "Deals and strategy", "count": 2}]}, "insights": [{"label": "Weighted tone", "value": "58/100", "tone": "positive", "text": "Constructive news tone"}, {"label": "Evidence confidence", "value": "84/100", "tone": "positive", "text": "23.94 effective stories after overlap and weighting."}, {"label": "Market reaction", "value": "News confirmed by price", "tone": "positive", "text": "Constructive news tone is being confirmed by positive weekly price action."}, {"label": "Primary event", "value": "Earnings", "tone": "positive", "text": "72/100 classification confidence."}, {"label": "Company focus", "value": "26", "tone": "positive", "text": "100% of weighted evidence is company-specific."}, {"label": "Evidence agreement", "value": "18/100", "tone": "positive", "text": "lower dispersion means the independent stories agree more closely."}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "+3.2% over one week, -0.2% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "Should Invesco Dividend Achievers ETF (PFM) Be on Your Investing Radar?"}], "updated_at": "2026-08-13T05:47:45.110020+00:00", "detail_intelligence": {"headline": "News confirmed by price", "summary": "Constructive news tone is drawn from 26 fresh independent stories, including 26 company-specific items across 3 publishers.", "status": "measured", "metrics": [{"label": "Weighted tone", "value": 58, "display": "58", "tone": "positive", "note": "Constructive news tone"}, {"label": "Evidence confidence", "value": 84, "display": "84", "tone": "positive", "note": "high confidence"}, {"label": "Company focus", "value": 100, "display": "100%", "tone": "positive", "note": "26 direct stories"}, {"label": "Evidence agreement", "value": 82, "display": "82", "tone": "positive", "note": "18/100 dispersion"}], "confidence_drivers": [{"label": "Sample depth", "value": 100, "note": "23.94 effective stories"}, {"label": "Source breadth", "value": 60, "note": "3 independent publishers"}, {"label": "Direct relevance", "value": 100, "note": "company-specific evidence share"}, {"label": "Freshness", "value": 79, "note": "recency-weighted evidence"}, {"label": "Agreement", "value": 82, "note": "cross-story consistency"}, {"label": "Source independence", "value": 27, "note": "lower publisher concentration"}], "freshness": 79, "source_independence": 27, "timeline": [{"date": "2026-07-24", "label": "24 Jul", "count": 0, "score": null, "tone": "neutral", "x": 42.0, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-25", "label": "25 Jul", "count": 0, "score": null, "tone": "neutral", "x": 87.8, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-26", "label": "26 Jul", "count": 0, "score": null, "tone": "neutral", "x": 133.6, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-27", "label": "27 Jul", "count": 0, "score": null, "tone": "neutral", "x": 179.4, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-28", "label": "28 Jul", "count": 0, "score": null, "tone": "neutral", "x": 225.2, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-29", "label": "29 Jul", "count": 0, "score": null, "tone": "neutral", "x": 271.0, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-30", "label": "30 Jul", "count": 0, "score": null, "tone": "neutral", "x": 316.8, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-31", "label": "31 Jul", "count": 0, "score": null, "tone": "neutral", "x": 362.6, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-01", "label": "01 Aug", "count": 0, "score": null, "tone": "neutral", "x": 408.4, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-02", "label": "02 Aug", "count": 0, "score": null, "tone": "neutral", "x": 454.2, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-03", "label": "03 Aug", "count": 0, "score": null, "tone": "neutral", "x": 500.0, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-04", "label": "04 Aug", "count": 0, "score": null, "tone": "neutral", "x": 545.8, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-05", "label": "05 Aug", "count": 0, "score": null, "tone": "neutral", "x": 591.6, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-06", "label": "06 Aug", "count": 0, "score": null, "tone": "neutral", "x": 637.4, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-07", "label": "07 Aug", "count": 0, "score": null, "tone": "neutral", "x": 683.2, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-08", "label": "08 Aug", "count": 0, "score": null, "tone": "neutral", "x": 729.0, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-09", "label": "09 Aug", "count": 0, "score": null, "tone": "neutral", "x": 774.8, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-10", "label": "10 Aug", "count": 2, "score": 72, "tone": "positive", "x": 820.6, "y": 95.0, "volume_height": 8.0, "volume_y": 258.0}, {"date": "2026-08-11", "label": "11 Aug", "count": 10, "score": 65, "tone": "positive", "x": 866.4, "y": 107.7, "volume_height": 40.0, "volume_y": 226.0}, {"date": "2026-08-12", "label": "12 Aug", "count": 13, "score": 53, "tone": "neutral", "x": 912.2, "y": 129.5, "volume_height": 52.0, "volume_y": 214.0}, {"date": "2026-08-13", "label": "13 Aug", "count": 1, "score": 58, "tone": "positive", "x": 958.0, "y": 120.4, "volume_height": 4.0, "volume_y": 262.0}], "timeline_points": "820.6,95.0 866.4,107.7 912.2,129.5 958.0,120.4", "timeline_has_signal": true, "timeline_start": "24 Jul", "timeline_mid": "03 Aug", "timeline_end": "13 Aug", "momentum": {"label": "Establishing", "tone": "neutral", "recent_score": 59, "prior_score": null, "delta": null, "recent_count": 26, "prior_count": 0, "volume_delta": 26}, "freshness_buckets": [{"label": "Last 24 hours", "count": 9, "share": 35}, {"label": "1 to 3 days", "count": 17, "share": 65}, {"label": "4 to 7 days", "count": 0, "share": 0}, {"label": "8 to 30 days", "count": 0, "share": 0}], "source_profile": [{"label": "finance.yahoo.com", "count": 21, "share": 81, "score": 59, "tone": "positive"}, {"label": "nasdaq.com", "count": 3, "share": 12, "score": 54, "tone": "neutral"}, {"label": "seekingalpha.com", "count": 2, "share": 8, "score": 63, "tone": "positive"}], "event_profile": [{"label": "Earnings", "count": 9, "share": 35, "score": 69, "tone": "positive"}, {"label": "Regulatory and legal", "count": 8, "share": 31, "score": 50, "tone": "neutral"}, {"label": "Market update", "count": 5, "share": 19, "score": 60, "tone": "positive"}, {"label": "Deals and strategy", "count": 2, "share": 8, "score": 71, "tone": "positive"}, {"label": "Analyst action", "count": 2, "share": 8, "score": 45, "tone": "neutral"}], "topics": [{"label": "Pharma", "count": 14, "share": 54}, {"label": "Clinical Trials", "count": 9, "share": 35}, {"label": "Earnings", "count": 8, "share": 31}, {"label": "Biotech", "count": 7, "share": 27}, {"label": "Fda Approval", "count": 6, "share": 23}, {"label": "Regulation", "count": 5, "share": 19}, {"label": "Obesity", "count": 5, "share": 19}, {"label": "Revenue Growth", "count": 3, "share": 12}, {"label": "Healthcare", "count": 3, "share": 12}, {"label": "Diabetes", "count": 3, "share": 12}], "supporting": [{"label": "Direct evidence", "text": "26 current stories are mapped specifically to LLY."}, {"label": "Source breadth", "text": "The read spans 3 publishers rather than depending on one outlet."}, {"label": "Narrative agreement", "text": "Cross-story agreement is 82/100, indicating a comparatively coherent tape."}, {"label": "Price response", "text": "Constructive news tone is being confirmed by positive weekly price action."}], "tempering": [], "supporting_heading": "What supports the read", "tempering_heading": "What tempers the read", "latest_observation": {"title": "Should Invesco Dividend Achievers ETF (PFM) Be on Your Investing Radar?", "summary": "Designed to provide broad exposure to the Large Cap Value segment of the US equity market, the Invesco Dividend Achievers ETF (PFM) is a passively managed exchange traded fund launched on September 15, 2005. The fund is sponsored by Invesco. It has amassed assets over $812.25 million, making it one of the average sized ETFs attempting to match the Large Cap Value segment of the US equity market. Why Large Cap Value Large cap companies usually have a market capitalization above $10 billion. Considered a more stable option, large cap companies boast more predictable cash flows and are less volat", "url": "https://finance.yahoo.com/markets/stocks/articles/invesco-dividend-achievers-etf-pfm-102001482.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-13T10:20:01+00:00", "published_display": "13 Aug 2026 10:20", "sentiment": "positive", "sentiment_pct": 58, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.531, "duplicate_count": 1, "topics": ["Dividends", "Earnings Growth", "ETF", "Financials", "Healthcare", "Institutional Investors"]}, "article_count": 26, "updated_at": "2026-08-13T05:47:45.110020+00:00"}, "price_sentiment_path": {"available": true, "price_points": [{"x": 42.0, "y": 133.1, "label": "13 Feb 2026", "close": 1038.21, "index": 100.0}, {"x": 77.4, "y": 146.5, "label": "20 Feb 2026", "close": 1007.79, "index": 97.1}, {"x": 112.8, "y": 127.9, "label": "27 Feb 2026", "close": 1050.18, "index": 101.2}, {"x": 148.1, "y": 154.9, "label": "06 Mar 2026", "close": 988.63, "index": 95.2}, {"x": 183.5, "y": 157.3, "label": "13 Mar 2026", "close": 983.39, "index": 94.7}, {"x": 218.9, "y": 191.7, "label": "20 Mar 2026", "close": 905.14, "index": 87.2}, {"x": 254.3, "y": 204.2, "label": "27 Mar 2026", "close": 876.73, "index": 84.4}, {"x": 289.6, "y": 179.0, "label": "03 Apr 2026", "close": 933.97, "index": 90.0}, {"x": 325.0, "y": 177.3, "label": "10 Apr 2026", "close": 937.86, "index": 90.3}, {"x": 360.4, "y": 182.8, "label": "17 Apr 2026", "close": 925.44, "index": 89.1}, {"x": 395.8, "y": 201.7, "label": "24 Apr 2026", "close": 882.44, "index": 85.0}, {"x": 431.2, "y": 166.8, "label": "01 May 2026", "close": 961.67, "index": 92.6}, {"x": 466.5, "y": 173.3, "label": "08 May 2026", "close": 946.82, "index": 91.2}, {"x": 501.9, "y": 147.8, "label": "15 May 2026", "close": 1004.92, "index": 96.8}, {"x": 537.3, "y": 121.3, "label": "22 May 2026", "close": 1065.0, "index": 102.6}, {"x": 572.7, "y": 103.7, "label": "29 May 2026", "close": 1105.0, "index": 106.4}, {"x": 608.1, "y": 92.1, "label": "05 Jun 2026", "close": 1131.42, "index": 109.0}, {"x": 643.4, "y": 91.4, "label": "12 Jun 2026", "close": 1133.0, "index": 109.1}, {"x": 678.8, "y": 106.6, "label": "19 Jun 2026", "close": 1098.57, "index": 105.8}, {"x": 714.2, "y": 58.4, "label": "26 Jun 2026", "close": 1208.12, "index": 116.4}, {"x": 749.6, "y": 55.8, "label": "03 Jul 2026", "close": 1213.91, "index": 116.9}, {"x": 784.9, "y": 67.0, "label": "10 Jul 2026", "close": 1188.58, "index": 114.5}, {"x": 820.3, "y": 71.1, "label": "17 Jul 2026", "close": 1179.11, "index": 113.6}, {"x": 855.7, "y": 63.7, "label": "24 Jul 2026", "close": 1196.03, "index": 115.2}, {"x": 891.1, "y": 84.4, "label": "31 Jul 2026", "close": 1148.84, "index": 110.7}, {"x": 926.5, "y": 68.2, "label": "07 Aug 2026", "close": 1185.71, "index": 114.2}], "sentiment_points": [{"x": 733.0, "y": 111.6, "label": "29 Jun 2026", "score": 60}, {"x": 733.9, "y": 113.4, "label": "29 Jun 2026", "score": 59}, {"x": 735.2, "y": 113.4, "label": "30 Jun 2026", "score": 59}, {"x": 737.4, "y": 113.4, "label": "30 Jun 2026", "score": 59}, {"x": 738.2, "y": 111.6, "label": "30 Jun 2026", "score": 60}, {"x": 738.2, "y": 111.6, "label": "30 Jun 2026", "score": 60}, {"x": 739.0, "y": 115.3, "label": "30 Jun 2026", "score": 58}, {"x": 743.0, "y": 113.4, "label": "01 Jul 2026", "score": 59}, {"x": 753.1, "y": 117.1, "label": "03 Jul 2026", "score": 57}, {"x": 753.6, "y": 117.1, "label": "03 Jul 2026", "score": 57}, {"x": 753.7, "y": 115.3, "label": "03 Jul 2026", "score": 58}, {"x": 766.1, "y": 119.0, "label": "06 Jul 2026", "score": 56}, {"x": 766.8, "y": 120.8, "label": "06 Jul 2026", "score": 55}, {"x": 766.9, "y": 120.8, "label": "06 Jul 2026", "score": 55}, {"x": 767.1, "y": 120.8, "label": "06 Jul 2026", "score": 55}, {"x": 768.0, "y": 119.0, "label": "06 Jul 2026", "score": 56}, {"x": 773.6, "y": 115.3, "label": "07 Jul 2026", "score": 58}, {"x": 778.2, "y": 113.4, "label": "08 Jul 2026", "score": 59}, {"x": 778.5, "y": 115.3, "label": "08 Jul 2026", "score": 58}, {"x": 783.4, "y": 119.0, "label": "09 Jul 2026", "score": 56}, {"x": 788.7, "y": 117.1, "label": "10 Jul 2026", "score": 57}, {"x": 803.7, "y": 117.1, "label": "13 Jul 2026", "score": 57}, {"x": 808.7, "y": 120.8, "label": "14 Jul 2026", "score": 55}, {"x": 809.1, "y": 120.8, "label": "14 Jul 2026", "score": 55}, {"x": 819.3, "y": 117.1, "label": "16 Jul 2026", "score": 57}, {"x": 819.6, "y": 117.1, "label": "16 Jul 2026", "score": 57}, {"x": 819.8, "y": 119.0, "label": "16 Jul 2026", "score": 56}, {"x": 823.9, "y": 115.3, "label": "17 Jul 2026", "score": 58}, {"x": 830.0, "y": 115.3, "label": "18 Jul 2026", "score": 58}, {"x": 839.9, "y": 115.3, "label": "20 Jul 2026", "score": 58}, {"x": 844.1, "y": 122.6, "label": "21 Jul 2026", "score": 54}, {"x": 853.3, "y": 120.8, "label": "23 Jul 2026", "score": 55}, {"x": 853.8, "y": 122.6, "label": "23 Jul 2026", "score": 54}, {"x": 860.3, "y": 119.0, "label": "24 Jul 2026", "score": 56}, {"x": 870.9, "y": 120.8, "label": "27 Jul 2026", "score": 55}, {"x": 873.2, "y": 119.0, "label": "27 Jul 2026", "score": 56}, {"x": 884.7, "y": 117.1, "label": "29 Jul 2026", "score": 57}, {"x": 889.1, "y": 117.1, "label": "30 Jul 2026", "score": 57}, {"x": 889.8, "y": 117.1, "label": "30 Jul 2026", "score": 57}, {"x": 893.3, "y": 117.1, "label": "31 Jul 2026", "score": 57}, {"x": 895.2, "y": 117.1, "label": "31 Jul 2026", "score": 57}, {"x": 899.9, "y": 117.1, "label": "01 Aug 2026", "score": 57}, {"x": 901.6, "y": 115.3, "label": "02 Aug 2026", "score": 58}, {"x": 901.8, "y": 117.1, "label": "02 Aug 2026", "score": 57}, {"x": 903.8, "y": 115.3, "label": "02 Aug 2026", "score": 58}, {"x": 905.1, "y": 119.0, "label": "02 Aug 2026", "score": 56}, {"x": 908.6, "y": 119.0, "label": "03 Aug 2026", "score": 56}, {"x": 911.0, "y": 120.8, "label": "03 Aug 2026", "score": 55}, {"x": 912.3, "y": 119.0, "label": "04 Aug 2026", "score": 56}, {"x": 919.8, "y": 120.8, "label": "05 Aug 2026", "score": 55}, {"x": 948.0, "y": 107.9, "label": "11 Aug 2026", "score": 62}, {"x": 958.0, "y": 111.6, "label": "13 Aug 2026", "score": 60}], "price_path": "42.0,133.1 77.4,146.5 112.8,127.9 148.1,154.9 183.5,157.3 218.9,191.7 254.3,204.2 289.6,179.0 325.0,177.3 360.4,182.8 395.8,201.7 431.2,166.8 466.5,173.3 501.9,147.8 537.3,121.3 572.7,103.7 608.1,92.1 643.4,91.4 678.8,106.6 714.2,58.4 749.6,55.8 784.9,67.0 820.3,71.1 855.7,63.7 891.1,84.4 926.5,68.2", "sentiment_path": "733.0,111.6 733.9,113.4 735.2,113.4 737.4,113.4 738.2,111.6 738.2,111.6 739.0,115.3 743.0,113.4 753.1,117.1 753.6,117.1 753.7,115.3 766.1,119.0 766.8,120.8 766.9,120.8 767.1,120.8 768.0,119.0 773.6,115.3 778.2,113.4 778.5,115.3 783.4,119.0 788.7,117.1 803.7,117.1 808.7,120.8 809.1,120.8 819.3,117.1 819.6,117.1 819.8,119.0 823.9,115.3 830.0,115.3 839.9,115.3 844.1,122.6 853.3,120.8 853.8,122.6 860.3,119.0 870.9,120.8 873.2,119.0 884.7,117.1 889.1,117.1 889.8,117.1 893.3,117.1 895.2,117.1 899.9,117.1 901.6,115.3 901.8,117.1 903.8,115.3 905.1,119.0 908.6,119.0 911.0,120.8 912.3,119.0 919.8,120.8 948.0,107.9 958.0,111.6", "price_change": 14.2, "sentiment_change": 0, "latest_close": 1185.71, "start_label": "13 Feb", "mid_label": "15 May", "end_label": "07 Aug"}, "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}